Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.23.3
NON CONTROLLING INTEREST (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net loss attributable to the non-controlling interest     $ (3,108) $ (4,195)
BioCorRx Pharmaceuticals, Inc [Member]        
Net loss $ (2,397) $ (7,802) $ (5,692) $ (17,335)
Average Non-controlling interest percentage of profit/losses 24.20% 24.20% 24.20% 24.20%
Net loss attributable to the non-controlling interest $ (580) $ (1,888) $ (1,378) $ (4,195)
Joseph DeSanto MD [Member]        
Net loss $ (1,395)   $ (4,945)  
Average Non-controlling interest percentage of profit/losses 35.00%   35.00%  
Net loss attributable to the non-controlling interest $ (488)   $ (1,730)